AlloArc Orthopedics Note (Standard)
About this template
Sample note
Chief Complaints:
Follow-up.
Right knee pain.
Left knee aching.
HPI:
71-year-old male with a past medical history of type 2 diabetes mellitus, atrial fibrillation on apixaban, and coronary artery disease with a drug-eluting stent in 2019, presents to clinic for follow-up of bilateral knee osteoarthritis.
1. RIGHT KNEE OSTEOARTHRITIS:
- The July 2026 injection relieved pain for about 2 weeks, compared with about 2 months after earlier injections. Can walk about a block before stopping, now uses a cane, has throbbing night pain, and takes stairs one at a time.
- No benefit from acetaminophen 1000 mg three times daily. Right Synvisc-One November 2025 gave no benefit; eight weeks of physical therapy in spring 2025 produced no lasting improvement. Right unloader brace in 2025 was not tolerated.
- Right corticosteroid injections January 2026, April 2026, and 07/14/2026. Cardiology stopped meloxicam in 2024 because of apixaban 5 mg twice daily.
2. LEFT KNEE OSTEOARTHRITIS:
- Left knee aches but is tolerable; asks about viscosupplementation. Left corticosteroid injections April 2026 and 07/14/2026.
3. TYPE 2 DIABETES MELLITUS:
- Hemoglobin A1c 8.9% 09/15/2026; diabetes managed by Dr. Simone Guidry.
Review of Systems:
Musculoskeletal: Reports bilateral knee pain, throbbing night pain in the right knee, and limited walking and stair use.
Assessment:
ICD M17.0-Bilateral primary osteoarthritis of knee:
ICD E11.65-Type 2 diabetes mellitus with hyperglycemia:
Treatment/Plan:
ICD M17.0-Bilateral primary osteoarthritis of knee:
- Recommended right total knee replacement given persistent functional limitation after injections, Synvisc-One, therapy, and brace intolerance, with oral anti-inflammatory use constrained by apixaban. Patient elected surgery.
- Exam today: right knee small effusion, varus alignment, range of motion 5 to 110 degrees; left knee without effusion, range of motion 0 to 120 degrees.
- Deferred corticosteroid injection in either knee given A1c 8.9% (09/15/2026), which an injection can worsen, and diminishing benefit on the right.
- Discussed infection, blood clots, stiffness, and incomplete pain relief as operative risks; detailed consent discussion and signing planned at the pre-op visit.
- Deferred scheduling, because of infection risk, until A1c is under 8 and cardiac clearance is obtained.
- Requested cardiac clearance and perioperative apixaban instructions from cardiology (Dr. Paul Fontenot).
- Started diclofenac gel 1 percent four times daily for both knees and continued acetaminophen 1000 mg three times daily; topical diclofenac is acceptable with apixaban.
- Left knee viscosupplementation not recommended, as it is unlikely to help given no response on the right; insurance coverage is also uncertain.
- Follow-up in 3 months with repeat A1c; surgery to be scheduled once A1c is under 8 and cardiac clearance is received.
- Prior studies: Standing bilateral knee radiographs, 3 views, 07/14/2026: severe right medial compartment narrowing with osteophytes and varus alignment; moderate left medial compartment narrowing.
- Prior treatment history: right corticosteroid injections January 2026, April 2026, and 07/14/2026 (latest relief about 2 weeks); right Synvisc-One November 2025 (no benefit); physical therapy eight weeks in spring 2025 (no lasting improvement); right unloader brace 2025 (not tolerated); acetaminophen 1000 mg three times daily (ineffective); meloxicam (stopped by cardiology because of apixaban).
ICD E11.65-Type 2 diabetes mellitus with hyperglycemia:
- Advised working with Dr. Simone Guidry to improve glucose control; ordered repeat hemoglobin A1c in three months.
This sample note was written by the template’s author and screened for patient information before publishing. Actual output may vary depending on patient encounter and clinical context.